DUBLIN--(BUSINESS WIRE)--The "Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.
The global urinary incontinence & pelvic organ prolapse devices and equipment market was valued at about $0.5 billion in 2018 and is expected to grow to $0.63 billion at a CAGR of 6.1% through 2022. Major players in the market are Boston Scientific Corporation, Coloplast Group, Ethicon US, Bard Inc. (Becton, Dickinson and Company.) and C. R. Bard Inc.
Increased prevalence rate for Pelvic organ prolapse (POP) as well as for urinary incontinence (UI) disorders has been driving the growth of urinary incontinence and pelvic organ prolapse (POP) devices and equipment market. The increasing prevalence rate has led the manufacturers towards developing more accurate and efficient devices for the treatment of these disorders. The POP affects women of all ages, however, the old age women are more prone to POP disorders.
According to the US FDA reports, the number of women who have POP is expected to increase by 46%, to 4.9 million, by 2050. According to a 2017 report published by the American Urological Association (AUA/SUFU), the prevalence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The prevalence rate of stress urinary incontinence is high in poor nutritional status group, as it results in weakness of pelvic supports. This high prevalence rate is driving the demand for medical equipment for urinary incontinence and pelvic organ prolapse.
The urinary incontinence and pelvic organ prolapse devices and equipment market is being restrained by rising health issues due to the use of vaginal mesh for the treatment of UI and POP. Regulatory agencies such as FDA and NICE have devised new guidelines for the manufacturers to address these concerns. The vaginal mesh implants generally uses Polypropylene layer over the implants. Such vaginal mesh implants containing Polypropylene have caused severe medical complications in millions of women across the world, therefore, manufacturers are now forced to develop an alternative material, such as polyurethane, which is better suited to be used by women without any health complications for treatment of pelvic organ prolapse and urine incontinence.
For instance, on March 8 2019, C.R. Bard, one of the major players of urinary incontinence and pelvic organ prolapse devices and equipment industry, announced its exit from the market of manufacturing and sale of vaginal mesh products in all markets worldwide after facing lawsuits from various women campaign groups across the globe. These concerns about the safety of vaginal mesh are resulting in stringent manufacturing regulations and affecting sales, thus restraining the UI and POP devices and equipment market.
The urinary incontinence and pelvic organ prolapse devices and equipment industry is characterized by the increased use of several new technologies in recent years. There is a wide range of devices being developed to treat both POP and urinary incontinence. For instance, The Lyrette transurethral SUI system launched in 2017 led by Verathon Medical UK Ltd, is the only FDA approved treatment used for treatment of stress urinary incontinence (SUI) among women.
Devices such as such as Lyrette transurethral SUI system are used for procedures for incontinence. The treatment through Lyrette does not require the use of anesthesia or surgery instead it uses radiofrequency energy to tighten the tissue of the bladder. For the treatment of POP, companies are now focusing on using native tissue prolapse repair procedures instead of vaginal mesh after the adverse health issues from the usage of vaginal mesh were highlighted.
Regulatory bodies, such as the FDA in the US, regulates the manufacturing and safety guidelines for devices and equipment related to urinary incontinence and pelvic organ prolapse disorders. For instance, manufacturers are required to obtain pre market clearance (510(k)) of the tools specifically for implanting surgical mesh. FDA requires the manufacturers in urinary incontinence and pelvic organ prolapse devices and equipment industry to conduct post market studies to check the specific safety and effectiveness concerns related to surgical mesh used for the repair of POP.
For example, FDA regulations resulted in many companies taking down their product completely from the market and made companies like Coloplast and Acell to discontinue marketing of their products- Coloplast's Restorelle DirectFix Posterior and Acell Matristem's Pelvic Floor Repair Matrix respectively.
Key Topics Covered
1. Executive Summary
2. Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market Characteristics
3. Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market Size And Growth
3.1. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market Segmentation
4.1. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
- Urinary Incontinence Devices
- Pelvic Organ Prolapse Devices
4.2. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market, Segmentation Urinary Incontinence Devices By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
- Artificial urinary sphincters
- Electrical stimulation devices
- Urethral slings Catheters
4.3. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market, Segmentation Pelvic Organ Prolapse Devices By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
- Vaginal mesh
- Vaginal pessary
4.4. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market, Segmentation By Incontinence Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
- Stress Incontinence
- Urge Incontinence
- Overflow Incontinence
- Functional Incontinence
4.5. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
- Hospitals Clinics
- Ambulatory Surgical Centers
- Home use
5. Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market Regional And Country Analysis
5.1. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
Companies Mentioned
- Boston Scientific Corporation
- Coloplast Group
- Ethicon US
- Bard Inc. (Becton Dickinson & Company)
- C. R. Bard Inc. LLC. (Johnson & Johnson)
- Teleflex Incorporated
- Medtronic plc
- Covidien
- Cook Medical
- Neomedic
- CooperSurgical
- MedGyn
- Personal Medical Corp
- Integra LifeSciences
- Panpac Medical
- Medesign
- Smiths Medical
- Thomas Medical
- Kangge Medical
- Dr. Arabin
For more information about this report visit https://www.researchandmarkets.com/r/o76ifs
